Metastatic melanoma is managed with a combination of immunotherapy (CTLA-4 checkpoint inhibitor ipilimumab and PD-1 inhibitors nivolumab and pembrolizumab), targeted therapy (BRAF inhibitors vemurafenib, dabrafenib, and encorafenib), and chemotherapy (dacarbazine and temozolomide). The gene discussed is BRAF; the disease is melanoma.